Hilleman Lab scouts for partners to develop low-cost vaccines
Hilleman Laboratories today said it is looking to tie up with vaccine specialty companies and government agencies to fund a Rs 300 project for developing some low-cost vaccines in India.
Hilleman is a 50:50 joint venture fund between MSD Pharmaceuticals and UK-based Wellcome Trust.
“We are spending around Rs 300 crore over the next 4-5 years to develop low-cost vaccines. We are developing vaccines to treat rotavirus, cholera and meningitis,” Hilleman Laboratories CEO Davinde Gill told PTI here.
“For research we are looking for partners, namely pharma companies, vaccine specialty companies and government agencies, to collaborate and fund the project. We had received foundational grants from MSD Pharmaceuticals and Wellcome Trust, but now we want to be financially independent,” Gill said.
MSD Pharmaceuticals and Wellcome Trust have invested around Rs 700 crore nearly five years ago, which is now valued at around Rs 900 crore.
Photo by CDC Global, via Flickr